Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET140202 T cells in advanced HCC
NCT03998033Phase 1Terminated
- Sponsor
- Eureka Therapeutics, Inc.
- Start
- May 2019
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of et1402l1-artemis t cells in hepatocellular carcinoma (HCC), sponsored by Eureka Therapeutics, Inc. Primary endpoints: Incidence rates of adverse events at 28 days and Recommended phase 2 dose up to 2 years. Started May 2019; status: terminated.
02
Drugs
et1402l1-artemis t cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03998033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998033.